Melanoma Clinical Trials in Nashville, Tennessee

13 studies are recruiting for melanoma in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

   The goal of this study is determine the safety and tolerability of orally taken probiotic (R-5780) in patients currently on a PD-1 Pathway Checkpoint Inhibitor (checkpoint protein on immune cells called T cells) with Solid Tumors.

   Stage

   Phase 1

   Ages

   18 to 80

   Site

   Sarah Cannon Research Institute, Nashville, Tennessee

   Locations

   2 in total

   Run by

   Rise Therapeutics LLC

   See if you can join NCT06398418 on ClinicalTrials.gov

2. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

   This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   SCRI Oncology Partners, Nashville, Tennessee

   Locations

   90 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06172478 on ClinicalTrials.gov

3. Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

   This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Locations

   8 in total

   Run by

   Neonc Technologies, Inc.

   See if you can join NCT06047379 on ClinicalTrials.gov

4. A Study of BI 3810944 in Patients With Advanced Cancer

   This study is open to adults with advanced cancer (solid tumours) for whom previous treatment was not successful, or no treatment exists. The study tests different doses of BI 3810944 to find out which doses they can tolerate. Another purpose is to identify the most suitable dose of BI 3810944 and …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Tennessee Oncology, PLLC - Elliston Place Plaza DDU, Nashville, Tennessee

   Locations

   7 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT07224425 on ClinicalTrials.gov

5. A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute-Tennessee Oncology, Nashville, Tennessee

   Locations

   48 in total

   Run by

   Pierre Fabre Medicament

   See if you can join NCT04913285 on ClinicalTrials.gov

6. DESTINY-PANTUMOUR04

   This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world…

   Stage

   Not phased

   Ages

   18 to 130

   Site

   Research Site, Nashville, Tennessee

   Locations

   18 in total

   Run by

   AstraZeneca

   See if you can join NCT07124000 on ClinicalTrials.gov

7. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

   This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville, Tennessee

   Locations

   111 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT06246916 on ClinicalTrials.gov

8. A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

   The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Locations

   47 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT04895709 on ClinicalTrials.gov

9. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

   This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Vanderbilt University School of Medicine, Nashville, Tennessee

   Locations

   42 in total

   Run by

   Inhibrx Biosciences, Inc

   See if you can join NCT04198766 on ClinicalTrials.gov

10. Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

    This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to…

    Stage

    Phase 3

    Ages

    18 to 70

    Site

    SCRI Oncology Partners, Nashville, Tennessee

    Locations

    81 in total

    Run by

    Iovance Biotherapeutics, Inc.

    See if you can join NCT05727904 on ClinicalTrials.gov

11. A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

    This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment opti…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    SCRI Oncology Partners, Nashville, Tennessee

    Locations

    23 in total

    Run by

    Nested Therapeutics, Inc

    See if you can join NCT06326411 on ClinicalTrials.gov

12. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage

    Not phased

    Ages

    Any age

    Site

    Massive Bio SYNERGY-AI site, Nashville, Tennessee

    Locations

    68 in total

    Run by

    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

13. Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment

    The purpose of this research is to identify biological characteristics occurring in the initiation and progression of melanoma.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Vanderbitl-Ingram Cancer Center, Nashville, Tennessee

    Run by

    Vanderbilt-Ingram Cancer Center

    See if you can join NCT01205815 on ClinicalTrials.gov